title: [A study on the prevalence rates of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infections in intravenous drug users].
abstract: OBJECTIVE
  To study HIV, HBV and HCV infections in intravenous drug users.
  
  
  METHODS
  2025 blood samples from intravenous drug users were collected from Sichuan, Hunan, Guangxi and Xinjiang regions, and tested for anti-HIV, anti-HCV, HBsAg using enzyme-linked immuno-sobent assays (ELISAs).
  
  
  RESULTS
  The positive rates of anti-HIV,anti-HCV and HBsAg were14.7%-30.4%, 60.7%-85.5% and 6.6%-22.4% in the intravenous drug users, respectively. The co-infection rates of HIV/HBV, HIV/HCV, HCV/HBV and HIV/HCV/HBV were 0%-0.4%, 11.6%-27.2%, 2.3%-14.3% and 1.6%-4.8% respectively in this population.
  
  
  CONCLUSIONS
  The infection rates of HIV, HBV and HCV were higher in the intravenous drug users than that in general populations in the same regions, and HIV/HCV co-infection appeared most frequent in this population.
authors.affiliation: National Institute for the Control of Pharmaceutical and Biological Products, Beijing 100050, China.
authors.forename: You-Chun
authors.initials: YC
authors.lastname: Wang
authors.forename: Si-Hong
authors.initials: SH
authors.lastname: Xu
authors.forename: Xiu-Hua
authors.initials: XH
authors.lastname: Li
authors.forename: Ai-Jing
authors.initials: AJ
authors.lastname: Song
authors.forename: Xue-Rong
authors.initials: XR
authors.lastname: Jia
authors.forename: Hui
authors.initials: H
authors.lastname: Zhuang
mesh_terms: D002681:China / Q000453:epidemiology; D015658:HIV Infections / Q000453:epidemiology*; D006509:Hepatitis B / Q000453:epidemiology*; D006526:Hepatitis C / Q000453:epidemiology*; D006801:Humans; D015995:Prevalence; D015819:Substance Abuse, Intravenous